New diabetes clinical trial: Metabolic Effects of Switching From Injectable Semaglutide to Tirzepatide

Published on: 2026-10-22T04:00:00Z
Conditions: Obesity; Type 2 Diabetes (T2D)
Interventions: Drug: Tirzepatide
Sponsors: LMC Diabetes & Endocrinology Ltd.; Eli Lilly and Company
Active, not recruiting
https://ift.tt/pGsuPfM